相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sildenafil's impact on male infertility: what has changed in 20 years?
Nickolas D. Scherzer et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2019)
The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient's satisfaction: results from a randomized, two-administration route, cross-over clinical trial
Tommaso Cai et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2019)
Ocular side effects of Levitra® (vardenafil) - results of a double-blind crossover study in healthy male subjects
Gernot Roessler et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Utilization and prescription patterns of phosphidiesterase-5 inhibitor medications in the United States military health system
Jon Montgomery et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2018)
British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017
Geoff Hackett et al.
JOURNAL OF SEXUAL MEDICINE (2018)
Erectile Dysfunction: AUA Guideline
Arthur L. Burnett et al.
JOURNAL OF UROLOGY (2018)
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma? A systematic review and meta-analysis
Shijian Feng et al.
MEDICINE (2018)
Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies
Xinming Han et al.
ONCOTARGETS AND THERAPY (2018)
Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil
I. Moncada et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2018)
Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis
T. Deng et al.
NEOPLASMA (2018)
Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction
Faysal A. Yafi et al.
SEXUAL MEDICINE REVIEWS (2018)
The interaction between erectile dysfunction complaints and depression in men: a cross-sectional study about sleep, hormones and cl uality of life
J. H. Soterio-Pires et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2017)
Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction
Daniel P. Andersson et al.
HEART (2017)
Delivery of intracavernosal therapies using needle-free injection devices
D. O'Kane et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2017)
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
Stacy Loeb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure
Evelyn M. Flahavan et al.
UROLOGY (2017)
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
Stacy Loeb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence
Jung Ki Jo et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
R. Pofi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2016)
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma
Anton Pottegard et al.
BRITISH JOURNAL OF CANCER (2016)
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer
Yi Lian et al.
EUROPEAN UROLOGY (2016)
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
Stacy Loeb et al.
EUROPEAN UROLOGY (2016)
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Eugenio Ventimiglia et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
Simon G. Anderson et al.
HEART (2016)
The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy
Howard D. Pomeranz
JOURNAL OF NEURO-OPHTHALMOLOGY (2016)
Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015)
Konstantinos Hatzimouratidis et al.
JOURNAL OF SEXUAL MEDICINE (2016)
Melanoma in men treated with PDE5A inhibitors: A report from the RADAR (Research on Adverse Drug Events And Reports) project
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Histopathologic and Ultrastructural Changes in Seminiferous Tubules of Adult Male Albino Rats Following Daily Administration of Different Doses of Tadalafil
Amira Abulfotooh Eid et al.
UROLOGY (2016)
Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink
Anthony Matthews et al.
PLOS MEDICINE (2016)
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy
Andrea Gallina et al.
EUROPEAN UROLOGY (2015)
Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis
Liang Chen et al.
EUROPEAN UROLOGY (2015)
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma
Stacy Loeb et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A Non-Fatal Self-Poisoning Attempt with Sildenafil
Veerle Matheeussen et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2015)
Association Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy
Nawaaz A. Nathoo et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2015)
Acute Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase Type 5 Inhibitors
Ulka B. Campbell et al.
JOURNAL OF SEXUAL MEDICINE (2015)
Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study
Wayne J. G. Hellstrom et al.
JOURNAL OF UROLOGY (2015)
Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy
Uwe Michl et al.
JOURNAL OF UROLOGY (2015)
Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy
N. R. Miller et al.
EYE (2015)
Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials
Elisa Giannetta et al.
BMC MEDICINE (2014)
Alprostadil for the treatment of impotence
Vishwanath Hanchanale et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
SILDENAFIL OVERDOSE CAN CAUSE RHABDOMYOLYSIS AND SUBJECTIVE VISUAL PERCEPTION CHANGES
Chia-Luen Huang et al.
NEPHROLOGY (2014)
THERAPEUTIC EFFECT OF SILDENAFIL ON BLAST-INDUCED TINNITUS AND AUDITORY IMPAIRMENT
G. Mahmood et al.
NEUROSCIENCE (2014)
Sildenafil Use and Increased Risk of Incident Melanoma in US Men A Prospective Cohort Study
Wen-Qing Li et al.
JAMA INTERNAL MEDICINE (2014)
moderateA phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction
Wayne J. G. Hellstrom et al.
BJU INTERNATIONAL (2013)
Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis
JinQiu Yuan et al.
EUROPEAN UROLOGY (2013)
An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction
L. H. Belkoff et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Standardization of Vascular Assessment of Erectile Dysfunction Standard Operating Procedures for Duplex Ultrasound
Suresh C. Sikka et al.
JOURNAL OF SEXUAL MEDICINE (2013)
SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunction
Hartmut Porst et al.
JOURNAL OF SEXUAL MEDICINE (2013)
Hearing Loss With Phosphodiesterase-5 Inhibitors: A Prospective and Objective Analysis With Tadalafil
Jagdeep S. Thakur et al.
LARYNGOSCOPE (2013)
Ups and Downs of Viagra: Revisiting Ototoxicity in the Mouse Model
Adrian Au et al.
PLOS ONE (2013)
Histopathologic results of long-term sildenafil administration on rat inner ear
Salih Bakir et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2012)
Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats
M. A. M. Khalaf et al.
ANDROLOGIA (2012)
Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial
Chen Zhao et al.
BJU INTERNATIONAL (2012)
Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability
Run Wang et al.
JOURNAL OF SEXUAL MEDICINE (2012)
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction
Irwin Goldstein et al.
JOURNAL OF SEXUAL MEDICINE (2012)
10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 Inhibitors
Gregory Lowe et al.
JOURNAL OF SEXUAL MEDICINE (2012)
cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function
Mirko Jaumann et al.
NATURE MEDICINE (2012)
The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
Ajay Nehra et al.
MAYO CLINIC PROCEEDINGS (2012)
Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China
L. He et al.
ANDROLOGIA (2011)
Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A
Imanol Arozarena et al.
CANCER CELL (2011)
PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study
Marco Guazzi et al.
CIRCULATION-HEART FAILURE (2011)
Viagra Deafness-Sensorineural Hearing Loss and Phosphodiesterase-5 Inhibitors
Afroze Shah Khan et al.
LARYNGOSCOPE (2011)
The actual incidence of papaverine-induced priapism in patients with erectile dysfunction following penile colour Doppler ultrasonography
M. Kilic et al.
ANDROLOGIA (2010)
Adverse Drug Events Associated with Yohimbine-Containing Products: A Retrospective Review of the California Poison Control System Reported Cases
Thomas Kearney et al.
ANNALS OF PHARMACOTHERAPY (2010)
Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database
F. Giuliano et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Priapism: Pathogenesis, Epidemiology, and Management
Gregory A. Broderick et al.
JOURNAL OF SEXUAL MEDICINE (2010)
Phosphodiesterase inhibitors and the eye
Nathan M. Kerr et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2009)
Long-term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction
Michael Rooney et al.
JOURNAL OF SEXUAL MEDICINE (2009)
Cutaneous melanoma in the era of molecular profiling
John F. Thompson et al.
LANCET (2009)
Sudden Hearing Loss From PDE-5 Inhibitors: A Possible Cellular Stress Etiology
Patrick T. Maddox et al.
LARYNGOSCOPE (2009)
High dosage sildenafil induces hearing impairment in mice
Bin Na Hong et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: Results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study
Wayne J. G. Hellstrom et al.
EUROPEAN UROLOGY (2008)
Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient
Brandon K. Wills et al.
CLINICAL TOXICOLOGY (2007)
Cyclic nucleotide signaling mechanisms in trypanosomes: Possible targets for therapeutic agents
Sunil Laxman et al.
MOLECULAR INTERVENTIONS (2007)
A case of sensorineural deafness following ingestion of sildenafil
B. Mukherjee et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2007)
Characterization and functional role of androgen-dependent PDE5 activity in the bladder
Sandra Filippi et al.
ENDOCRINOLOGY (2007)
Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism
Arthur L. Burnett et al.
JOURNAL OF SEXUAL MEDICINE (2006)
An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients
Harin Padma-Nathan et al.
UROLOGY (2006)
Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy
L Gorkin et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction
A Laties et al.
JOURNAL OF SEXUAL MEDICINE (2006)
Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors
XJ Zhang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1
R Seyam et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2005)
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism
HC Champion et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function
SS du Plessis et al.
FERTILITY AND STERILITY (2004)
The interaction of the penetration enhancer DDAIP with a phospholipid model membrane
AM Wolka et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation
MA Blount et al.
MOLECULAR PHARMACOLOGY (2004)
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
E Bischoff
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2004)
The efficacy and safety of tadalafil: an update
CC Carson et al.
BJU INTERNATIONAL (2004)
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
WJG Hellstrom et al.
JOURNAL OF UROLOGY (2003)
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial
WJG Hellstrom et al.
UROLOGY (2003)
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes - A multicenter double-blind placebo-controlled fixed-dose study
I Goldstein et al.
DIABETES CARE (2003)
Fatal overdosage with sildenafil citrate (Viagra®):: first report and review of the literature
A Tracqui et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2002)
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses
GB Brock et al.
JOURNAL OF UROLOGY (2002)
IC351 (tadalafil, Cialis): update on clinical experience
H Porst
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2002)
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial
H Porst et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2001)
Drug therapy: Erectile dysfunction.
TF Lue
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study
CB Johannes et al.
JOURNAL OF UROLOGY (2000)
分享论文
